Discovery of novel TRPV1 modulators through machine learning-based molecular docking and molecular similarity searching.

Journal: Chemical biology & drug design
Published Date:

Abstract

The transient receptor potential vanilloid 1 (TRPV1) channel belongs to the transient receptor potential channel superfamily and participates in many physiological processes. TRPV1 modulators (both agonists and antagonists) can effectively inhibit pain caused by various factors and have curative effects in various diseases, such as itch, cancer, and cardiovascular diseases. Therefore, the development of TRPV1 channel modulators is of great importance. In this study, the structure-based virtual screening and ligand-based virtual screening methods were used to screen compound databases respectively. In the structure-based virtual screening route, a full-length human TRPV1 protein was first constructed, three molecular docking methods with different precisions were performed based on the hTRPV1 structure, and a machine learning-based rescoring model by the XGBoost algorithm was constructed to enrich active compounds. In the ligand-based virtual screening route, the ROCS program was used for 3D shape similarity searching and the EON program was used for electrostatic similarity searching. Final 77 compounds were selected from two routes for in vitro assays. The results showed that 8 of them were identified as active compounds, including three hits with IC values close to capsazepine. In addition, one hit is a partial agonist with both agonistic and antagonistic activity. The mechanisms of some active compounds were investigated by molecular dynamics simulation, which explained their agonism or antagonism.

Authors

  • Xinmiao Wei
    State Key Laboratory of NBC Protection for Civilian, Beijing, China.
  • Qifan Yang
    Department of Computer Science and Engineering, Northwest Normal University, Lanzhou, Gansu Province 730070, China.
  • Zhijiang Yang
    State Key Laboratory of NBC Protection for Civilian, Beijing, China.
  • Tengxin Huang
    State Key Laboratory of NBC Protection for Civilian, Beijing, China.
  • Hang Yang
    Department of Clinical Research Center, Dazhou Central Hospital, Dazhou 635000, China.
  • Liangliang Wang
    Department of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
  • Li Pan
  • Junjie Ding
    State Key Laboratory of NBC Protection for Civilian, Beijing, China.